Clinical Trial Detail

NCT ID NCT02568267
Title Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Advanced Solid Tumor

colorectal cancer

anaplastic large cell lymphoma

Therapies

Entrectinib

Age Groups: adult senior

Additional content available in CKB BOOST